Not for last Friday I don't think anyone reported them , the previous two weeks were:
Trx 621 619
Not 100% sure about the 297Nrx...could be a couple more or less.
Hoping someone will post last Fridays numbers
Seems only the M@R@NS with multiple ID's are suffering from your problem.
Lack of self esteem and a need to hide behind multiple ID's(on the same IP address)That's probably why yahoo gets confused. Or it could be that multiple ID posters gets reported frequently..
Suggest you take up cave painting since your posts give the impression that that's where your communication skills would fit the best.
Back to the WC in Ice hockey.
Total control right now.
Start of day drive down followed by cover.
Lunch drive down again followed by.......
Rinse and repeat
We need News or good earnings to move now.
Epi Pen revenues to Mylan are in excess of $1 billion annually.
Should TEVA gain approval for a Generic version of Epi Pen they
should capture (conservative estimate) 40% of the market
(pharmacies are required to provide the generic unless the brand
is stipulated by the physician and no doctor I have spoken with
advised they would stipulate the brand name).
So that is about $400+ million in revenue to TEVA and between
device sales and royalties on product sales ATRS will receive
about 10% (mostly bottom line) and that is $40+ million a year;
or a little over 30 cents a share. With a 20 X multiple - that is
value to ATRS of $6 a share.
IF I am wrong on the numbers or the multiple by a full 50% than
generic Epi Pen is worth $3 a share to ATRS - and we are now
selling at under $2.50 a share.
NOW isn't that alone enough compelling reason to buy and own
We have regulatory risk - and that is a big thing - no one can
depend on the FDA acting as we expect they should. But TEVA
is the leading generic drug company in the world and if they can't
get approval - nobody can - and it is a fact that they are buying
"significant" quantities of pre launch devices for their Epi-Pen and
both TEVA and Mylan indicated they expect a generic Epi-Pen
to be launched in 2015.
NOW nothing's a sure thing - but (forget my spell" and look at
the facts) -
NOW add the small but easily earned royalty from legacy products.
Add Otrexup - not tearing the cover off the ball, but the launch is
going as the company predicted (minus Wotton's exaggerated
forecast) - slow and building.
Add Sumatriptan which should soon be approved and launched
by TEVA with a 50 / 50 split with ATRS.
Add 5 & 10 mg HGH to be launched by Ferring this year.
Add what should be the "best in class" testosterone replacement
drug - QST - which will be selling (if approved) into a multi- billion
dollar market - and we should get a very lucrative licensing deal
for primary care and keep the plum or urology for "in house"
Add the CNS drugs (very early stage and unknown) and the life
cycle extension deal announced some months ago.
AND WE HAVE A VERY, VERY INESPCNSIVE STOCK. IF YOU
PRESENTED THESE ASSETS AND OPPORTUNITIES TO ANYONE
AND TOLD THEM WE HAVE 130 MILLION SHARES OUT - NO
DEBT - AND TO GUESS AT THE PRICE OF THE STOCK - THEY
WOULD SURELY PICK A NUMBER FAR IN EXCESS OF TODAY'S
WE WILL GET TO HIGHER NUMBERS - CONSIDERING THE ABOVE
IT IS JUST ABOUT AS MUCH OF A SURE THING THAT EXISTS IN THE
your maturity is reflected in your posts and equally so among your friends.
And you have come up with nothing so far, so plug away rearview.
See you at the Rich As A Troll Ladder,
If you added 38,000 Shares to what I presume would be an already large holding.
I'll be a number if steps below :o)
Lots of Short covering today.
Sentiment: Strong Buy
Maybe bull can ask them for a reason why Teva EPI wont be approved as he so boldly stated.
I asked him why but he does not seem to have an answer...could be because he's full of bull as his ID states.